CRUSH!!MDS 

Title: Predicting Response to Your Myelodysplastic Syndromes (MDS) Treatment

Principal Investigator: Dr. Sangmin Lee
Contact: Stephanie Corrigan
Phone: (646) 962-2082
Email: crushmds@med.cornell.edu
Sponsor: Aplastic Anemia and MDS International Foundation

The primary aim of this study is to explore and characterize the methylation profiles of myelodysplastic syndrome patients via an online, community outreach process, with CRUSH!!MDS as a platform.  We aim to characterize the methylation profiles of myelodysplastic syndrome patients who have previously failed hypomethylating agents (HMA).  We will characterize methylation profiles of subjects’ granulocytes in peripheral blood, utilizing methylation platform developed by Dr. Joseph Scandura at Weill Cornell Medical College.

To see if you qualify for the study, please review the informed consent form and record any questions you might have for the study team. After reviewing the informed consent form, please complete and submit the study questionnaire. Upon receipt of your questionnaire a member of the study team will be in contact to discuss next steps.

Key Eligibility

• Men and women age 18 and older
• Pathologically confirmed MDS (<20% blasts in bone marrow, peripheral blood, or both)
• Detailed eligibility reviewed when you contact the study team

Disease Status: Myelodysplastic syndrome with HMA failure
Study Status: Open
IRB#: 1411015656
Expiration: October 25, 2016